PL
PLLWF.US Polarean Imaging plc
- Market cap
- USD 7.97M
- P/E
- -
- P/B
- 1.09x
- ROE
- -271.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2025.
Is PLLWF.US undervalued?
Graham numberThe Graham number of Polarean Imaging plc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Polarean Imaging plc fundamental analysis
No fundamental analysis for Polarean Imaging plc yet.
Polarean Imaging plc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Polarean Imaging plc
Polarean Imaging plc operates as a drug-device manufacturer and service provider for noble gas hyperpolariser devices in Canada, the United Kingdom, and the United States. The company engages in the research, development, and commercialization of novel imaging solutions with a non-invasive and radiation-free functional imaging platform. It also offers XENOVIEW, a hyperpolarized contrast agent indicated for use with magnetic resonance imaging (MRI) for evaluation of lung vent…
Full company profilePolarean Imaging plc financial statements
2025 annualized: Fiscal year 2025 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2025, the balance sheet is the latest quarter. Figures change when the annual report is published.
Polarean Imaging plc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 902K | 881K | 1.24M | 2.44M | 2.30M | 1.06M | 1.19M | 1.03M | 891K | 3.09M | 2.52M |
| Gross Profit | 594K | 392K | 940K | 1.81M | 1.38M | 710K | 508K | 348K | 335K | 1.42M | 383K |
| Operating Income | -627K | -1.06M | -3.92M | -5.27M | -6.01M | -6.62M | -14.3M | -13.7M | -12.6M | -8.75M | -22.4M |
| EBITDA | -617K | -1.05M | -3.54M | -4.67M | -5.24M | -5.67M | -13.4M | -12.6M | -11.2M | -7.56M | -20.4M |
| Net Income | -1.07M | -1.06M | -3.96M | -5.45M | -6.10M | -6.53M | -14.0M | -13.9M | -11.9M | -8.54M | -21.5M |
| EPS | -1.49 | -0.99 | -0.14 | -0.08 | -0.06 | -0.04 | -0.07 | -0.07 | -0.06 | -0.01 | -0.02 |
| Balance Sheet | |||||||||||
| Total Assets | 1.49M | 474K | 6.79M | 9.83M | 7.04M | 10.9M | 34.5M | 22.5M | 10.9M | 15.8M | 11.1M |
| Total Liabilities | 769K | 1.06M | 3.35M | 2.04M | 2.45M | 2.15M | 2.79M | 3.23M | 2.58M | 3.65M | 3.19M |
| Shareholders' Equity | 359K | -586K | 3.44M | 7.79M | 4.59M | 8.73M | 31.7M | 19.3M | 8.30M | 12.1M | 7.90M |
| Cash & Short-term Investments | 912K | 97.8K | 960K | 876K | 1.96M | 6.28M | 28.9M | 16.5M | 6.17M | 12.1M | 7.29M |
| Total Debt | 144K | 105K | 1.10M | 5.21K | 121K | 221K | 490K | 359K | 217K | 504K | 441K |
| Cash Flow | |||||||||||
| Operating Cash Flow | -505K | -760K | -2.62M | -4.68M | -4.57M | -5.79M | -12.3M | -12.3M | -10.4M | -5.61M | -20.5M |
| Capital Expenditure | 10.9K | 10.9K | 16.8K | 6.55K | 401K | 65.5K | 541K | 63.9K | 78.9K | 198K | 164K |
| Free Cash Flow | -505K | -771K | -2.63M | -4.68M | -4.97M | -5.86M | -12.8M | -12.3M | -10.5M | -5.81M | -20.7M |
| Ratios | |||||||||||
| ROE | -298.6% | - | -115.0% | -70.0% | -133.0% | -74.8% | -44.2% | -72.0% | -143.2% | -70.3% | -271.5% |
| ROA | -72.0% | -223.3% | -58.3% | -55.5% | -86.7% | -60.1% | -40.6% | -61.7% | -109.2% | -54.1% | -193.5% |
| Net Profit Margin | -118.7% | -120.3% | -319.9% | -223.6% | -265.2% | -618.4% | -1,182.4% | -1,346.1% | -1,334.0% | -276.4% | -852.0% |
| Debt to Equity | 0.40x | - | 0.32x | 0.00x | 0.03x | 0.03x | 0.02x | 0.02x | 0.03x | 0.04x | 0.06x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Polarean Imaging plc dividends
Polarean Imaging plc has not paid dividends in the last 9 fiscal years.
Last stock split: 293:250 on Jul 16, 2024.
Who owns Polarean Imaging plc
- Insiders 47.52%
- Institutions 12.93%
- Public & others 39.56%
- Shares outstanding 1.21B
- Free float 714M
Polarean Imaging plc company profile
- Company name
- Polarean Imaging plc
- Ticker
- PLLWF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 26
- Fiscal year end
- December
- Address
- 27-28 Eastcastle Street, London, United Kingdom, W1W 8DH
- Phone
- 919 206 7900
- Website
- polarean.com
About Polarean Imaging plc
Polarean Imaging plc operates as a drug-device manufacturer and service provider for noble gas hyperpolariser devices in Canada, the United Kingdom, and the United States. The company engages in the research, development, and commercialization of novel imaging solutions with a non-invasive and radiation-free functional imaging platform. It also offers XENOVIEW, a hyperpolarized contrast agent indicated for use with magnetic resonance imaging (MRI) for evaluation of lung ventilation in adults and pediatric patients aged 12 years and older; chest coil; Polarean 9820 Xenon hyperpolarizer that is designed to deliver up to 3 litres of hyperpolarized 129Xe per hour; and Polarean 2881 polarization measurement station, which provides a calibrated measurement of the polarization of hyperpolarized gas within the dose delivery inhalation bag. Polarean Imaging plc was incorporated in 2016 and is based in London, the United Kingdom.
Polarean Imaging plc management
8- Dr. Kenneth Paul West Ph.D.Non-Executive Chairman of the Board · born 1957
- Dr. Christopher Richard Von Jako Ph.D.CEO & Director · born 1970
- Mr. Charles Fremont Osborne Jr.CFO & Director · born 1966
- Mr. Neil WadehraVice President of Operations · born 1980
- Dr. Kiarash Emami Ph.D.Vice President of Technology & Applications · born 1975
- Mr. Alex DusekChief Commercial Officer · born 1967
- Dr. Chase Hall M.D.Chief Medical Advisor
- Mr. Stephen AustinCompany Secretary